The Cholesterol Disorder With a Median Age at Death of 37, and Why 96% of Patients Fall Short of LDL Goals

Key Takeaway

The most comprehensive global registry on homozygous familial hypercholesterolemia reveals that, despite contemporary lipid-lowering therapies, 96% of patients fail to achieve LDL cholesterol targets, facing a median age of death of just 37 years. Lifelong extreme LDL exposure entirely abolishes the traditional cardiovascular survival advantage observed in females, while the geography of a child’s birth continues to dictate life expectancy.

A 12-Year-Old with the Arteries of an Octogenarian

Consider a 12-year-old girl evaluated in clinic for yellowish subcutaneous nodules over her knuckles and Achilles tendons. Both of her parents report a personal history of high cholesterol. Her lipid panel reveals an LDL cholesterol level of 14.7 mmol/L—approximately 570 mg/dL. She has never smoked, has no history of diabetes, and runs track, yet her coronary arteries and aortic valve have endured this overwhelming atherogenic burden since before birth. This is not a hypothetical case; she embodies the statistical median of a landmark international registry on homozygous familial hypercholesterolemia (HoFH), an ultra-rare disorder affecting roughly 1 in 300,000 individuals.^[2]Among deceased patients in this registry, the median age at death was just 37 years. For a condition diagnosable through a routine, low-cost lipid…